Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia and Cantab Announce Drug Discovery Collaboration

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Partnership to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections.

Cantab has recently been awarded a grant of £2.3m from the Biomedical Catalyst Fund to continue its promising programme in this area.

Polymyxins have become an important ‘last resort’ therapy for certain MDR Gram-negative infections, but suffer from complex pharmacokinetics and dose-limiting toxicities which often lead to sub-optimal therapy. Polymyxins are the only effective antibiotic to act specifically on the lipopolysaccharide of Gram-negative bacteria and, given the rise of problem infections with Gram-negative bacteria, it is timely to harness this mechanism of action into improved therapeutic entities.
 
Selcia will provide medicinal chemistry resource to:

•    Generate a range of polymyxin-based entities to continue the optimisation of  antibacterial activity against MDR strains in vitro
•    Optimise the most promising entities to improve antibacterial activity in vivo
•    Optimise therapeutic index
•    Optimise to give a clinical candidate meeting all aspects of the target product profile

Dr Hans Fliri, CEO of Selcia, commented, “We are delighted that Cantab has selected Selcia as its discovery partner for this project and we look forward to a successful conclusion to the collaboration.”

Dr Mike Dawson, CEO of Cantab, commented, “When we wanted to complement our internal medicinal chemistry efforts we identified Selcia as our partner of choice for this project as it has a highly successful track-record working on complex medicinal chemistry projects and identifying development candidates from challenging starting points.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia Introduces New Prolyl Isomerase Screening Service
Selcia Limited has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (“PPIases”).
Friday, February 01, 2013
Selcia and NeuroVive to Develop New Mitochondrial Medicines
Selcia Limited and NeuroVive Pharmaceutical AB have signed a research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.
Monday, October 10, 2011
Selcia and ExonHit Therapeutics Announce Successful Fragment Screening Collaboration
Successful completion of a drug discovery project with ExonHit Therapeutics using Selcia’s fragment screening technology.
Thursday, April 21, 2011
Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board
Simon Saxby brings successful leadership and executive management experience to the role of Selcia’s CEO and Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board.
Thursday, February 24, 2011
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences Inc. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Tuesday, November 30, 2010
Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain
Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.
Thursday, November 25, 2010
Simon Saxby Joins Board at Selcia
Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Monday, June 28, 2010
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!